药明康德（603259）(02359)发布公告，于2025年8月18日斥资2999.76万元回购A股股份30.79万股，每股 回购价格为96.65-99.12元。 ...

智通财经APP讯，药明康德(02359)发布公告，于2025年8月18日斥资2999.76万元回购A股股份30.79万 股，每股回购价格为96.65-99.12元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 第 1 頁 共 12 頁 v 1.3.0 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | 303,367 | | | | | | | | 0.01 % | RMB | 65.96 | ...

序号代码名称最新价涨跌幅主力净流入主力净占比1300759康龙化成30.942.356867.71万元4.17%2600721 百花医药8.7810.036396.54万元25.72%3300015爱尔眼科13.221.34784.89万元2.6%4301235华康洁净 33.2813.393316.13万元5.67%5600763通策医疗46.182.263071.04万元4.73%6301096百诚医药57.12- 10.621489.28万元1.33%7688238和元生物8.566.87869.84万元3.25%8301333诺思格56.751.29781.52万元 5.13%9002524光正眼科4.58-0.43657.94万元7.93%10688246嘉和美康36.723.15585.47万元3.17% 8月18日，医疗服务行业上涨1.26%，今日主力资金流出14.05亿元，成分股33只上涨，9只下跌。 主力资金净流出居前的分别为药明康德（4.78亿元）、创新医疗（4.1亿元）、凯莱英（1.75亿元）、三 博脑科（1.57亿元）、睿智医药（5473.37万元）。 来源：金融界 ...

Group 1 - The innovation drug concept remains active, with significant market movements and various sectors showing strong performance, particularly in the financial and innovation drug sectors [1] - The estimated market size for China's innovative drug and medical device market in 2024 is approximately 162 billion yuan, with predictions to exceed 1 trillion yuan by 2035 [1] - Multiple innovative drug ETFs have seen substantial inflows, with a total net inflow of 7.551 billion yuan in August, indicating strong investor interest [2] Group 2 - Over 80 innovative drug concept stocks have seen an average price increase of 4.42% since August, with some stocks like Nanmo Biology and Shunlian Bio rising over 40% [3] - Nanmo Biology has experienced the highest price increase of 97.5% in August, driven by its advanced technology platform for gene research [3] - Several innovative drug stocks, including Borui Pharmaceutical and Anke Bio, have received significant institutional attention, with over 10 institutions conducting research on them [4] Group 3 - Borui Pharmaceutical has signed a strategic cooperation agreement with Hanyu Pharmaceutical, enhancing its supply capabilities for future product launches [4] - Anke Bio has reached a nationwide exclusive agency agreement for a new innovative drug, which is expected to be the first long-acting follicle-stimulating hormone preparation in China [4] - More than half of the innovative drug concept stocks have received net buying from financing, with notable amounts for companies like WuXi AppTec and Borui Pharmaceutical [4]

数据显示，截至2025年7月31日，上证180指数(000010)前十大权重股分别为贵州茅台(600519)、恒瑞医药(600276)、中国平安(601318)、紫金矿业(601899)、 药明康德(603259)、招商银行(600036)、长江电力(600900)、兴业银行(601166)、中芯国际(688981)、京沪高铁(601816)，前十大权重股合计占比25.4%。 | 股票代码 | 股票简称 | 涨跌幅 | 权重 | | --- | --- | --- | --- | | 600519 | 贵州茅台 | 0.61% | 4.92% | | 201899 | 紫美时,不 | -0.80% | 2.96% | | 601318 | 中国平安 | 0.55% | 2.75% | | 600276 | 恒瑞失药 | 0.14% | 2.62% | | 600036 | 招商银行 | 0.18% | 2.62% | | 600900 | 长江电力 | -0.07% | 2.28% | | 603259 | 药明康德 | 0.51% | 1.97% | | 601166 | 兴业银行 | 1.16% | 1. ...

作者：金股通 本文源自：金融界 截至8月18日开盘一小时，主力资金流出前20的股票分别为：卧龙电驱（-15.18亿元）、天风证券 （-14.58亿元）、东方财富（-11.00亿元）、衢州发展（-6.03亿元）、中银证券（-5.19亿元）、工业富 联（-4.52亿元）、上海电气（-4.50亿元）、金发科技（-4.13亿元）、指南针（-4.07亿元）、凯美特气 （-4.03亿元）、万通发展（-3.61亿元）、英维克（-3.37亿元）、国盛金控（-3.32亿元）、东山精密 （-3.06亿元）、恒宝股份（-2.95亿元）、药明康德（-2.90亿元）、中国神华（-2.61亿元）、中电鑫龙 （-2.54亿元）、宁波韵升（-2.52亿元）、飞龙股份（-2.42亿元）。 ...

恒生医疗ETF（513060）高开，盘中持续震荡，截至发稿，上涨近1.5%，成交额近5亿元，换手率超 6%。成分股中半数上涨，亚盛医药-B、四环医药涨超8%；联邦制药、平安好医生、时代天使、再鼎医 药等个股跟涨，涨幅均超3%。 相关机构发文表示，当下的政策主线，政策+BD双轮驱动。目录双轨（基本医保+商保创新药）意味 着"能进医保走医保、谈不成进商保"的支付闭环雏形已定，释放"真创新更易放量"的信号；时间轴看， 8月公示收官→三季度评审与谈判→10–11月结果发布，政策催化将贯穿3–4个月窗口。对A+H公司而 言，已在公示名单内或具有新增适应症者，阶段性更易获得资金关注。 结构与节奏上，业绩线与事件线叠加。创新药在医保/商保支付"双轨"与MNC数百亿美元级BD"干火 药"共振下，中国创新药板块系统性重估仍在继续；互联网医疗（平台+药房/到家）在高增长与盈利改 善带动下，是H股医药里相对收益的主赛道之一；设备耗材侧，带量集采在部分品类节奏持续，短线对 单一产品依赖度高、议价能力弱的企业形成估值压制，但中长期关注出清后龙头份额提升与国产替代的 结构性机会。 上周港股冲高回落，恒指再度刷新阶段新高。港股三大指数今日 ...

□本报记者 王宇露 上周市场表现强势，中证新华社民族品牌工程指数上涨3.64%，报1780.22点。阳光电源（300274）、东 方财富（300059）、中际旭创（300308）等成分股上周表现优异；下半年以来，中际旭创、科沃斯 （603486）、药明康德（603259）等成分股涨幅居前。 展望后市，机构认为，后续市场风险偏好和交投情绪或持续高涨，流动性充裕将成为驱动力，市场仍存 在着较多的投资机会，在流动性驱动后，基本面驱动有望接棒。 多只成分股表现强势 上周市场大幅上涨，上证指数上涨1.70%，深证成指上涨4.55%，创业板指上涨8.58%，沪深300指数上 涨2.37%，品牌工程指数上涨3.64%，报1780.22点。 下半年以来，中际旭创上涨63.20%，排在涨幅榜首位；科沃斯上涨57.31%，居次席；药明康德上涨 40.62%；阳光电源、达仁堂、泰格医药涨逾30%；我武生物（300357）和恒瑞医药（600276）分别上涨 29.22%和22.16%；智飞生物（300122）、国瓷材料、盾安环境、石头科技、东方财富、复星医药、泸 州老窖（000568）、康泰生物（300601）、步长制药（60385 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][39]. Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a total A-share increase of 2.04% and a decline of 0.84% in the biotechnology sector [1][30]. - The brain-computer interface (BCI) industry is rapidly developing, supported by recent government policies and successful clinical trials, indicating significant growth potential [2][11]. - The report emphasizes the importance of innovative drugs and their supporting infrastructure, highlighting the positive impact of adjustments in medical insurance and commercial health insurance on domestic innovative drug sales [3][39]. Summary by Sections Market Performance - The overall A-share market increased by 2.04%, while the biotechnology sector decreased by 0.84%, indicating a weaker performance relative to the market [1][30]. - The current price-to-earnings (P/E) ratio for the pharmaceutical sector is 38.77x, which is at the 80.28th percentile of its historical valuation over the past five years [1][35]. Brain-Computer Interface Industry - The BCI industry is characterized by a growing number of supportive policies and technological advancements, with a focus on both invasive and non-invasive methods [2][11]. - The market for non-invasive BCIs is the primary research direction, accounting for 86% of the market share [11][16]. - The potential market size for serious medical applications of BCIs is estimated between $15 billion and $85 billion, while consumer medical applications could reach $25 billion to $60 billion [16]. Key Companies and Investment Recommendations - **Mindray Medical (300760.SZ)**: Rated "Outperform" with projected net profits increasing from 116.7 billion in 2024 to 161.9 billion in 2027 [4]. - **WuXi AppTec (603259.SH)**: Rated "Outperform" with expected net profits rising from 93.5 billion in 2024 to 145.1 billion in 2027 [4]. - **Aier Eye Hospital (300633.SZ)**: Rated "Outperform" with a focus on expanding its service network and enhancing service prices [39]. - **Huitai Medical (688617.SH)**: Rated "Outperform" with a strong focus on electrophysiology and interventional medical devices [40]. - **Innovative Medical (002173.SZ)**: Rated "Outperform" with ongoing clinical trials and expected registration of medical devices [39].